MA5-12259

antibody from Invitrogen Antibodies

Targeting: CD4

Western blot

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: MA5-12259 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD4 Monoclonal Antibody (4B12)
Antibody type: Monoclonal
Antigen: Other
Description: MA5-12259 targets CD4 in IHC (P), WB and FACS applications and shows reactivity with Human samples. The MA5-12259 immunogen is stimulated human leukocytes.
Reactivity: Human
Host: Mouse
Isotype: IgG
Antibody clone number: 4B12
Vial size: 500 µL
Concentration: Conc. Not Determined
Storage: 4° C

CD4 protein structure - MA5-12259 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD4 in K562 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a CD4 monoclonal antibody (Product # MA5-12259) at a dilution of 1:2 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD4 in PBMC cells (green) compared to an isotype control (blue). Human blood was collected, combined with a hydrophilic polysaccharide, centrifuged, transferred to a conical tube and washed with PBS. 50 µL of cell solution was added to each tube at a dilution of 2x10^7 cells/mL, followed by the addition of 50 µL of isotype control and primary antibody (Product # MA5-12259) at a dilution of 1:2. Cells were incubated for 30 min at 4ºC and washed with a cell buffer, followed by incubation with a DyLight 488-conjugated goat anti-mouse IgG (H+L) secondary for 30 min at 4ºC in the dark. FACS analysis was performed using 400 µL of cell buffer.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD4 in PBMC cells (green) compared to an isotype control (blue). Human blood was collected, combined with a hydrophilic polysaccharide, centrifuged, transferred to a conical tube and washed with PBS. 50 µL of cell solution was added to each tube at a dilution of 2x10^7 cells/mL, followed by the addition of 50 µL of isotype control and primary antibody (Product # MA5-12259) at a dilution of 1:2. Cells were incubated for 30 min at 4ºC and washed with a cell buffer, followed by incubation with a DyLight 488-conjugated goat anti-mouse IgG (H+L) secondary for 30 min at 4ºC in the dark. FACS analysis was performed using 400 µL of cell buffer.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7. Distribution of CD4 + CD25 + CD27 + regulatory T cells in lymph nodes and synovial tissues. (A-C) Serial sections of a reactive lymph node stained with antibodies to CD4 (A), CD25 (B), and CD27 (C). (D-H) Serial sections of synovial biopsy from a JIA patient showing a T and B lymphoid aggregate stained with antibodies to CD3 (D), CD20 (E), CD27 (F), CD25 (G), and CD4 (H). (I) A consecutive section stained with CD25 (red) and CD27 (green) by two-color fluorescence.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 UVR-induced inflammation recruits CD4 + FOXP3 + T regulatory cells during the post-resolution phase in human skin; however, CD4 + GATA3 + T cells are the dominant phenotype . (a) Representative immunofluorescent images of CD207 + Langerhans cells post-UVR. (b) Quantification of CD207 + post-UVR exposure ( N = 12 healthy volunteers for each time point). (c) Quantification of the total number of CD4 + cells on immunohistochemical staining ( N = 12 or 13 healthy volunteers for each time point). (d) Representative immunofluorescent images of CD4 + FOXP3 + cells post-UVR (e) Quantification of the number of dual-positive CD4 + FOXP3 + cells post-UVR ( N = 8 healthy volunteers for each time point). (f) Percentage of CD4 + FOXP3 + cells of total CD4 + cells post-UVR ( N = 8 healthy volunteers for each time point). (g) Representative immunofluorescent images of CD4 + GATA3 + cells post-UVR. (h) Percentage of CD4 + GATA3 + cells of total CD4 + cells post-UVR ( N = 7 or 8 healthy volunteers for each time point). Data are mean +- SEM. Experiments were performed once. Scale bars = 50 um. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Macroscopic and microscopic analysis of 1-fluoro-2,4-dinitrobenzene-induced ACD after 24h sensitisation with a 10% solution and 2h challenge with a 1% solution, shown in images which best represent the changes, selected from images of four skin tissue samples from one minipig A - Macroscopic images of day-17 skin samples; B - Histopathological image with Masson's trichrome staining. Spongiosis is marked with a yellow arrowhead; acanthosis is marked with a black arrowhead; perivascular immune cell infiltration at the epidermis-dermis junction is marked with a blue arrowhead; C - Immunohistochemistry. CD4+ lymphocytes, major basic protein (MBP)+ eosinophils, and CD11b+ macrophages are marked by black arrow heads. Scale bar = 100 mum